(Wall Street Journal) – Crowley will take on his biggest role yet in March, when he becomes chief executive officer of Biotechnology Innovation Organization, a powerful trade group whose members are mostly small health-focused companies. Crowley will succeed Rachel King, who has served as interim CEO since Dr. Michelle McMurry-Heath resigned after disagreements with some BIO board members. (Read More)